Generate Biomedicines, Inc.
GENB
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -18.08% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -18.08% | ||||
| Cost of Revenue | 23.46% | ||||
| Gross Profit | -33.10% | ||||
| SG&A Expenses | 33.28% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 25.21% | ||||
| Operating Income | -33.14% | ||||
| Income Before Tax | -39.38% | ||||
| Income Tax Expenses | -50.00% | ||||
| Earnings from Continuing Operations | -39.27% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -89.81% | ||||
| Net Income | -47.41% | ||||
| EBIT | -33.14% | ||||
| EBITDA | -34.58% | ||||
| EPS Basic | 34.34% | ||||
| Normalized Basic EPS | 22.69% | ||||
| EPS Diluted | 34.34% | ||||
| Normalized Diluted EPS | 22.69% | ||||
| Average Basic Shares Outstanding | 97.83% | ||||
| Average Diluted Shares Outstanding | 97.83% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||